SCHEMBL22606629

SCHEMBL22606629

Cc1cc2nc(CNC(=O)C3CCN(Cc4ccc5[nH]ccc5c4)CC3)[nH]c2cc1C

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHRM4 P08173 2/20 0.49
▸ FAAH O00519 1/20 0.45
▸ LMNA P02545 3/20 0.45
▸ CHRM1 P11229 3/20 0.44
▸ CHRM3 P20309 3/20 0.44
▸ CHRM2 P08172 1/20 0.44
▸ CHRM5 P08912 2/20 0.43
▸ MCHR1 Q99705 2/20 0.42
▸ SSTR5 P35346 1/20 0.42
▸ PARP1 P09874 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ MCHR2 Q969V1 1/20 0.41
▸ EGFR P00533 1/20 0.40
▸ FLT1 P17948 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22606644 0.91 LMNA (0.56) CHRM4FAAHLMNACHRM1CHRM3
SCHEMBL22606649 0.90 CHRM4 (0.51) CHRM4FAAHLMNACHRM1CHRM3
SCHEMBL22584713 0.88 CHRM4 (0.50) CHRM4FAAHMCHR1SSTR5PARP1
SCHEMBL22607012 0.87 CHRM4 (0.50) CHRM4FAAHLMNACHRM1CHRM3
SCHEMBL22606800 0.82 CHRM4 (0.55) CHRM4FAAHCHRM1CHRM3CHRM2
SCHEMBL22606795 0.78 SOS1 (0.48) MAPT
SCHEMBL22606972 0.77 SSTR5 (0.51) CHRM4FAAHCHRM1CHRM3CHRM2
SCHEMBL22606683 0.76 CHRM4 (0.56) CHRM4FAAHCHRM1CHRM3CHRM2
SCHEMBL22606652 0.76 ACKR3 (0.57) CHRM4FAAHCHRM1CHRM3CHRM2
SCHEMBL24424559 0.74 KDM4E (0.52) CHRM4LMNAMAPTALDH1A1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200339537-A1 NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF ENHANCEDBIO, INC. (KR) 2020-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339537-A1 NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF NEDD4, PFDN1, PF4 CHRM4 3387/4885FAAH 4096/4885LMNA 4612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback